Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis

European Journal of Pharmacology

Volumn 591, Issue 1-3, 2008, Pages 132-135

  Hasanein, Parisa ^a   Shahidi, Siamak ^b   Komaki, Alireza ^b   Mirazi, Naser ^a  

^a BU ALI SINA UNIVERSITY   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

(Rat); Antinociception; Cholestasis; Endocannabinoid; Fatty acid amide hydrolase

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID CB2 RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRUG VEHICLE; ENDOCANNABINOID; ENDOCANNABINOID INHIBITOR; FATTY ACID AMIDASE INHIBITOR; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; ENZYME INHIBITION; LATENT PERIOD; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; CARBAMATES; CHOLESTASIS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; MALE; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 48749116524     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.061     Document Type: Article

References (36)

1. Bergasa N.V., Rothman R.B., Vergalla J., Xu H., Swain M.G., and Jones E.A. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J. Hepatol. 15 (1992) 220-224
2. Bergasa N.V., Alling D.W., Vergalla J., and Jones E.A. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J. Hepatol. 20 (1994) 85-90
3. Corchero J., Manzanares J., and Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit. Rev. Neurobiol. 16 (2004) 159-172
4. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9371-9376
5. Dehpour A.R., Akbarloo N., and Ghafourifar P. Endogenous nitric oxide modulates naloxone-precipitated withdrawal signs in a mouse model with acute cholestasis. Behav. Pharmacol. 9 (1998) 77-80
6. Dehpour A.R., Mani A.R., Amanlou M., Nahavandi A., Amanpour S., and Bahadori M. Naloxone is protective against indomethacin-induced gastric damage in cholestatic rats. J. Gastroenterol. 34 (1999) 178-181
7. Dehpour A.R., Sadeghipour H.R., Nowroozi A., and Akbarloo N. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum. Psychopharmacol. 15 (2000) 423-428
8. Dehpour A.R., Samini M., Rastegar H., Ardeshiri A.J., Roushanzamir F., Jorjani M., and Ahmadiani A. Effect of NMDA receptor antagonist on naloxone-precipitated withdrawal signs in cholestatic mice. Hum. Psychopharmacol. 15 (2000) 213-218
9. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., and Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
10. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313 (2005) 352-358
11. Gingold A.R., and Bergasa N.V. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci. 73 (2003) 2741-2747
12. Hasanein P., Parviz M., Keshavarz M., Javanmardi K., Allahtavakoli M., and Ghaseminejad M. Modulation of cholestasis-induced antinociception in rats by two NMDA receptor antagonists: MK-801 and magnesium sulfate. Eur. J. Pharmacol. 554 (2007) 123-127
13. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., and Rice K. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 1932-1936
14. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 121 (2002) 173-190
15. Hohmann A.G., and Suplita R.L. An endocannabinoid mechanism for stress-induced analgesia. AAPS J. 8 (2006) E693-E708
16. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J.F., Walker J.M., Holmes P.V., Crystal J.D., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 435 (2005) 1108-1112
17. Javanmardi K., Parviz M., Sadr S.S., Keshavarz M., Minaii B., and Dehpour A.R. Involvement of N-methyl-d-aspartate receptors and nitric oxide in the rostral ventromedial medulla in modulating morphine pain-inhibitory signals from the periaqueductal grey matter in rats. Clin. Exp. Pharmacol. Physiol. 32 (2005) 585-589
18. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147 (2006) 281-288
19. Jhaveri M.D., Richardson D., and Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 152 (2007) 624-632
20. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., and Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9 (2003) 76-81
21. Lichtman A.H., Leung D., Shelton C.C., Saghatelian A., Hardouin C., Boger D.L., and Cravatt B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311 (2004) 441-448
22. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
23. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74 (2005) 411-432
24. Monhemius R., Azami J., Green D.L., and Roberts M.H. CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res. 908 (2001) 67-74
25. Namiranian K., Samini M., Mehr S.E., Gaskari S.A., Rastegar H., Homayoun H., and Dehpour A.R. Mesenteric vascular bed responsiveness in bile duct-ligated rats: roles of opioid and nitric oxide systems. Eur. J. Pharmacol. 423 (2001) 185-193
26. Neff G.W., O'Brien C.B., Reddy K.R., Bergasa N.V., Regev A., Molina E., Amaro R., Rodriguez M.J., Chase V., Jeffers L., and Schiff E. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am. J. Gastroenterol. 97 (2002) 2117-2119
27. Nelson L., Vergnolle N., D'Mello C., Chapman K., Le T., and Swain M.G. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J. Hepatol. 44 (2006) 1141-1149
28. Rastegar H., Homayoun H., Afifi M., Rezayat M., and Dehpour A.R. Modulation of cholestasis-induced antinociception by CCK receptor agonists and antagonists. Eur. Neuropsychopharmacol. 12 (2002) 111-118
29. Russo R., Loverme J., La Rana G., Compton T.R., Parrott J., Duranti A., Tontini A., Mor M., Tarzia G., Calignano A., and Piomelli D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther. 322 (2007) 236-242
30. Smith F.L., Fujimori K., Lowe J., and Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 60 (1998) 183-191
31. Swain M.G., Rothman R.B., Xu H., Vergalla J., Bergasa N.V., and Jones E.A. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 103 (1992) 630-635
32. Swain M.G., MacArthur L., Vergalla J., and Jones E.A. Adrenal secretion of BAM-22P, a potent opioid peptide, is enhanced in rats with acute cholestasis. Am. J. Physiol. 266 (1994) G201-G205
33. Thornton J.R., and Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ 297 (1988) 1501-1504
34. Thornton J.R., and Losowsky M.S. Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J. Hepatol. 8 (1989) 53-59
35. Walker J.M., and Huang S.M. Cannabinoid analgesia. Pharmacol. Ther. 95 (2002) 127-135
36. Welch S.P., and Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 848 (1999) 183-190